[US-헬스케어] 06/04 Wall St. Recap

Eli Lilly (LLY) continues to demonstrate robust momentum, primarily driven by the market dominance of its obesity therapeutics, specifically Zepbound and Mounjaro. Despite the recent surge in share price, institutional confidence remains high, as evidenced by recent price target upgrades from major financial institutions like Bank of America.

The company’s valuation reflects its position as a leader in the GLP-1 receptor agonist market, which is experiencing unprecedented demand. While concerns regarding “overvaluation” are common after such a rally, the long-term growth trajectory—supported by a strong pipeline and expanding manufacturing capacity—suggests that the stock’s premium is justified by its fundamental earnings growth potential. Investors should focus on supply chain scaling and competitive positioning as the primary catalysts for sustained performance.

Novo Nordisk’s recent momentum is driven by the successful clinical and regulatory progression of its oral GLP-1 (Wegovy pill). The significant outperformance in Q1 2026 earnings, coupled with the strategic expansion into the UAE market and formal EU regulatory backing, underscores the company’s ability to scale its oral delivery platform. While short-term stock volatility persists due to competitive pressures from telehealth providers like Hims & Hers, the transition from injectable to oral administration represents a critical competitive moat that will likely sustain long-term market leadership and improve patient adherence.

Amgen (AMGN) is currently navigating a complex landscape defined by strong commercial momentum in its core portfolio, offset by regulatory and legal headwinds. While the 34% surge in Repatha sales underscores the company’s ability to drive growth in its cardiovascular franchise, this is being tempered by recent safety concerns regarding Tavneos in Japan and ongoing tax litigation risks.

From a valuation perspective, the stock’s recent volatility reflects a tug-of-war between its long-term compounding growth potential and the market’s caution regarding regulatory scrutiny. Investors should monitor whether the current price levels represent a genuine undervaluation or if the legal uncertainties warrant a more conservative risk premium. We maintain a neutral stance until there is greater clarity on the resolution of tax disputes and the long-term impact of the safety warnings on the drug’s market penetration.

UnitedHealth Group (UNH) continues to demonstrate robust fundamental resilience despite recent volatility and institutional portfolio adjustments. While Berkshire Hathaway’s exit has drawn market attention, the bullish sentiment from major financial institutions like Bank of America, driven by strong Q2 earnings expectations, suggests that the market is shifting its focus toward long-term EPS growth and operational efficiency.

The company’s strategic outlook for 2026 remains a critical catalyst, reinforcing a narrative of sustained margin expansion and market leadership. Despite sector-wide regulatory pressures—such as the recent Blue Cross Blue Shield settlement—UNH’s diversified business model and dominant market share provide a defensive moat that mitigates idiosyncratic risks. Investors should view the current valuation as a reflection of the company’s ability to navigate complex healthcare headwinds while maintaining a clear trajectory for shareholder value creation.

Pfizer (PFE) is currently undergoing a strategic pivot as it transitions away from pandemic-era tailwinds toward a more diversified portfolio. The recent Q1 financial results have surpassed market expectations, signaling that the company’s cost-cutting initiatives and focus on oncology and hematology are beginning to stabilize the bottom line.

While the company faces ongoing pressure from regulatory shifts in global markets, the successful integration of recent acquisitions and the advancement of its vaccine pipeline provide a clearer path to long-term growth. Investors should monitor how Pfizer leverages its R&D efficiency to offset the patent cliff and sustain its dividend yield, which remains a key pillar of its investment thesis.